Skip to content

Serratus Anterior Plane Block in Pediatric Patients

Serratus Anterior Plane Block in Pediatric Patients Undergoing Thoracic Surgeries: A Randomized Controlled Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04444635
Enrollment
70
Registered
2020-06-23
Start date
2020-06-14
Completion date
2021-06-20
Last updated
2021-06-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesia, Local

Keywords

Serratus anterior plane block, Pediatric, Thoracotomy

Brief summary

The aim of this work is to study the efficacy of ultrasound guided serratus anterior plane block in pediatric patients undergoing thoracic surgeries. It is a randomized controlled trial.

Detailed description

It is a prospective randomized controlled study. It is designed to estimate and compare the analgesic effect of single shot serratus anterior plane block in pediatric patients undergoing thoracic surgeries with fentanyl infusion versus fentanyl infusion alone as the control group. Our primary outcome will be the total dose of intra-operative fentanyl boluses. Randomization will be achieved by using an online random number generator. Blindness will be achieved by patient codes which will be placed into sequentially numbered sealed opaque envelopes by a research assistant who is not involved in the study. A physician not involved in patient management will be responsible for opening the envelope and give the instructions contained within each envelope to the anaesthesiologist who is expert in doing the serratus anterior plane block in patients included within the block group. This expert anaesthesiologist will not be involved in collecting data but another anaesthesia doctor will be responsible for patient management and collecting the intraoperative and postoperative data.

Interventions

PROCEDURESerratus Anterior Plan Block+ Fentanyl infusion

After induction of anesthesia, the patients will be put on the lateral position with the diseased side up. A linear ultrasound transducer will be placed in a sagittal plane over the mid-clavicular region of the thoracic cage. Then counting down ribs till the fifth rib will be identified in the mid-axillary line. The following muscles will be identified overlying the fifth rib: the latissimus dorsi (superficial and posterior),teres major (superior) and serratus muscles (deep and inferior). Under complete sterile conditions, the needle (25 G needle) will be introduced in-plane with respect to the ultrasound probe targeting the plane superficial to the serratus anterior muscle. Then, 2 mg/kg of 0.25% bupivacaine will be injected with continuous ultrasound guidance. In addition to continuous fentanyl infusion

DRUGFentanyl

Continuous fentanyl infusion throughout the surgical procedure.

Sponsors

Cairo University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Masking description

Blindness will be achieved by patient codes which will be placed into sequentially numbered sealed opaque envelopes by a research assistant who is not involved in the study. A physician not involved in patient management will be responsible for opening the envelope and give the instructions contained within each envelope to the anaesthesiologist who is expert in doing the serratus anterior plane block in patients included within the block group. This expert anaesthesiologist will not be involved in collecting data but another anaesthesia doctor will be responsible for patient management and collecting the intraoperative and postoperative data.

Eligibility

Sex/Gender
ALL
Age
6 Months to 3 Years
Healthy volunteers
No

Inclusion criteria

* Age: 6 months-3 years. * American Society of anesthesiology (ASA) I and II. * Pediatric patients undergoing thoracic surgeries (with anterior thoracotomy incision).

Exclusion criteria

* Patients whose parents or legal guardians refusing to participate. * Preoperative mechanical ventilation. * Known or suspected coagulopathy. * Infection at the site of injection. * Known or suspected allergy to any of the studied drugs. * Elevated liver enzymes more than the normal values. * Procedures with anticipated significant hemodynamic stability. * Renal function impairment (Creatinine value more than 1.2mg/dl or blood urea nitrogen (BUN) more than 20mg/dl).

Design outcomes

Primary

MeasureTime frameDescription
The total dose of postoperative operative fentanyl consumption in the first 24 hours.12 monthsThe total dose of postoperative operative fentanyl consumption in micrograms in the first 24 hours will be calculated

Secondary

MeasureTime frameDescription
Total dosage of additional fentanyl boluses usage in micrograms intraoperatively12 monthsTotal dosage of additional fentanyl boluses usage in micrograms intraoperatively
First rescue analgesia12 monthsTime (in minutes) to 1st rescue analgesia (morphine) post operatively which will be defined to be the elapsed time between stoppage of fentanyl infusion and a patient FLACC score equal or more than 4.
Pain assessment postoperatively by Face, Leg, Activity, Cry, Consolability (FLACC) score, minimum is zero, and maximum is 6.12 monthsPain assessment at 30 min, 60 min, 2 hours, 4hours, 8hours postoperatively by FLACC score.
Intra and postoperative heart rate.12 monthsIntra and postoperative heart rate.
Intraoperative and postoperative systolic blood pressure.12 monthsIntraoperative and postoperative systolic blood pressure.

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026